NPLOC4 and cancer: By setting up the phenotypic screening involving the known drug target (NPL4) as the readout, we were able to identify a clinically relevant compound—cannabidiol (CBD), as the most likely cause of unwanted interference with ongoing cancer treatment with disulfiram (Antabuse), the anticancer effects of which are currently tested in multiple ongoing preclinical studies and clinical trials [30].